Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Top Performance

Predictions

sell
Cellectis Nom.

Start price
Target price
Perf. (%)
€2.39
01.11.23
-
01.11.24
-1.42%
10.11.23

Could be worthwhile Investment >10% per year
Bankster 
01.11.23 50%
sell
Cellectis Nom.

Start price
Target price
Perf. (%)
€1.96
01.11.23
€1.00
01.11.24
20.31%
11.11.23

Good culture
Below average Management
Few uniques
Probably not worthwhile Investment
me8 
01.11.23 0%
buy
Deciphera Pharmaceuticals

Start price
Target price
Perf. (%)
€11.30
31.10.23
€20.79
31.10.24
110.62%
21.06.24

Stifel Nicolaus 
31.10.23 50%
buy
Deciphera Pharmaceuticals

Start price
Target price
Perf. (%)
€10.74
31.10.23
€28.29
31.10.24
117.98%
21.06.24

HC Wainwright 
31.10.23 50%
buy
Deciphera Pharmaceuticals

Start price
Target price
Perf. (%)
€10.74
31.10.23
-
31.10.24
117.98%
21.06.24

Jonestrading 
31.10.23 50%
buy
Bayer AG

Start price
Target price
Perf. (%)
€40.81
31.10.23
-
31.10.24
-18.31%
20.11.23

Could be worthwhile Investment >10% per year
Future proof or reliable business model
Growths faster than the competition
Significant cyclical dependencies
fenjal 
31.10.23 50%
buy
Zoetis Inc. A

Start price
Target price
Perf. (%)
€147.65
30.10.23
€183.81
30.10.24
13.21%
30.08.24

Stifel Nicolaus 
30.10.23 50%
buy
Deciphera Pharmaceuticals

Start price
Target price
Perf. (%)
€11.11
30.10.23
€21.66
30.10.24
114.22%
21.06.24

Piper Sandler 
30.10.23 50%
buy
AbbVie Inc.

Start price
Target price
Perf. (%)
€136.30
30.10.23
€184.51
30.10.24
31.82%
08:16

Morgan Stanley 
30.10.23 50%
sell
Novan Inc

Start price
Target price
Perf. (%)
€0.001
30.10.23
-
30.10.24
-
19.09.23

StockNews.com 
30.10.23 50%
buy
AbbVie Inc.

Start price
Target price
Perf. (%)
€136.00
30.10.23
€160.21
30.10.24
32.11%
08:16

Barclays PLC 
30.10.23 50%
buy
Bristol-Myers Squibb

Start price
Target price
Perf. (%)
€48.25
30.10.23
€65.03
30.10.24
-2.69%
08:00

The Goldman Sachs Group, Inc. 
30.10.23 50%
buy
G1 Therapeutics

Start price
Target price
Perf. (%)
€1.64
30.10.23
€4.71
30.10.24
290.55%
28.08.24

Wedbush 
30.10.23 50%
buy
Coherus Bioscien.

Start price
Target price
Perf. (%)
€3.26
30.10.23
-
30.10.24
-53.86%
10.11.23

Could be very worthwhile Investment >20% year
Bankster 
30.10.23 50%
buy
Atara Biotherapeutics Inc.

Start price
Target price
Perf. (%)
€1.21
30.10.23
-
30.10.24
-82.87%
11.11.23

Could be worthwhile Investment >10% per year
blaugold 
30.10.23 50%
buy
Sarepta Therapeutics

Start price
Target price
Perf. (%)
€121.95
29.10.23
€150.00
31.03.26
-
30.10.23

Could be very worthwhile Investment >20% year
BiotechBee 
29.10.23 50%
buy
Eledon Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€2.52
29.10.23
€2.80
30.09.25
-
30.10.23

Could be very worthwhile Investment >20% year
BiotechBee 
29.10.23 60%
buy
ImmunityBio Inc.

Start price
Target price
Perf. (%)
€2.30
29.10.23
€4.00
30.06.26
247.39%
29.04.24

Could be very worthwhile Investment >20% year
BiotechBee 
29.10.23 50%
buy
Coherus Bioscien.

Start price
Target price
Perf. (%)
€3.26
29.10.23
€4.00
29.10.24
-52.75%
11.11.23

Could be worthwhile Investment >10% per year
Good culture
Capable Management
Few uniques
me8 
29.10.23 0%
sell
AEterna Zentaris Inc.

Start price
Target price
Perf. (%)
€1.37
29.10.23
-
29.10.24
36.30%
02.05.24

StockNews.com 
29.10.23 50%
buy
Dr. Reddy's Laboratories Ltd. ADR

Start price
Target price
Perf. (%)
€61.00
28.10.23
-
28.10.24
21.22%
30.08.24

StockNews.com 
28.10.23 50%
sell
Affimed N.V.

Start price
Target price
Perf. (%)
€0.29
28.10.23
-
28.10.24
89.77%
08.03.24

StockNews.com 
28.10.23 50%
sell
Moleculin Biotech Inc

Start price
Target price
Perf. (%)
€0.43
28.10.23
-
28.10.24
0.47%
21.03.24

StockNews.com 
28.10.23 50%
sell
PTC Therapeutics Inc.

Start price
Target price
Perf. (%)
€17.20
28.10.23
€8.00
28.10.24
-4.07%
11.11.23

Probably not worthwhile Investment
Revenue decline/stagnation expected
Lower EBIT Margin than peer group
negative Cash Flow expected
nvestor 
28.10.23 50%
sell
Bristol-Myers Squibb

Start price
Target price
Perf. (%)
€49.80
27.10.23
€47.31
27.10.24
-5.72%
08:00

Morgan Stanley 
27.10.23 50%